BowTiedBiotech
BowTiedBiotech Podcast
The Race to Tackle Neuroinflammation in Modern Neuroscience
0:00
Current time: 0:00 / Total time: -17:19
-17:19

The Race to Tackle Neuroinflammation in Modern Neuroscience

Biology Overview & Translation to Therapeutics

Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.

We are now publishing 4-5x per week according to the following cadence:

  • Mondays: BioBucks: Stock Analysis & Biotech Catalysts

  • Wednesdays: CRISPR Corner: Monthly gene editing news

  • Thursdays: Insiders Track: Public & Private Biotech Markets

  • Fridays: Sweat Equity: Your Weekly Biotech Fix

  • Sundays: Building Biotech: Strategic Topics

In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.

Please help spread the work by subscribing and hitting the share button if you are enjoying content!

Image

Welcome to the Bowtied Biotech Podcast, where we dive into the most cutting-edge innovations shaping the future of healthcare and medicine. Today, we're exploring the fierce and exciting race to tackle neuroinflammation—a field at the heart of modern neuroscience. As biopharmaceutical research zeroes in on the role of inflammation in neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, new therapeutic strategies targeting pathways such as TREM2, PGRN, and the NLRP3 inflammasome are redefining the treatment landscape. Join us as we break down the science, the setbacks, and the opportunities driving this pivotal area of research, with insights into the latest developments and what they mean for the future of brain health.

📣🎙️ TODAY’S POCAST:

[ 00:00 ] Introduction
[ 00:07 ] Why Neuroinflammation Matters
[ 00:33 ] Defining Neuroinflammation
[ 01:00 ] Balance of Inflammation
[ 02:12 ] Research Advances
[ 02:20 ] TREM2 Overview
[ 03:38 ] TREM2 Trial Setback
[ 04:25 ] PGRN Function
[ 05:50 ] PGRN in Diseases
[ 06:18 ] NLRP3 Inflammasome
[ 07:19 ] NLRP3 Inhibitors
[ 08:39 ] CSF1R Target
[ 09:55 ] Complement System Role
[ 12:20 ] Immune System Balance
[ 13:12 ] Personalized Medicine
[ 13:41 ] Lifestyle and Brain Health
[ 14:28 ] Ethical Considerations
[ 16:48 ] Closing Thoughts

Please help us grow our community & earn FREE subscription to BowtiedBiotech - sharing is caring!

Share

CONCLUSION

We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!

As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com

ABOUT BOWTIEDBIOTECH

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

DISCLAIMER

None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.  

TOP BOWTIEDBIOTECH NEWSLETTERS

Discussion about this podcast

BowTiedBiotech
BowTiedBiotech Podcast
1-2x Biotech Focused Podcast: Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends